Cochran Collaboration ESA Meta-Analysis Underscores Survival Risk
Executive Summary
A meta-analysis of patient level data from over 10,000 clinical trial patients suggests that use of erythropoiesis-stimulating agents may have an adverse survival impact in the still-approved uses in supportive care for oncology